Paul McNab, who serves as Executive Vice President at Viavi Solutions Inc (NASDAQ: VIAV), completed a sale of 3,551 shares of common stock on March 2, 2026. The shares changed hands at $32.89 apiece, producing a total transaction amount of $116,792, according to a Form 4 filing submitted to the Securities and Exchange Commission. After the disposition, McNab directly holds 18,198 shares of Viavi common stock.
The share sale coincides with Viavi trading close to a 52-week high reported at $31.42, and follows a year in which the stock delivered a 166% return. InvestingPro analysis cited in company commentary indicates the stock appears overvalued relative to its Fair Value.
Viavi also recently released financial results for the second quarter of fiscal 2026 that beat consensus estimates. The company posted earnings per share of $0.22, outpacing the $0.19 forecast, and generated revenue of $369.3 million versus the $365.25 million analysts had anticipated. These results were highlighted alongside comments from management at recent investor meetings where an upbeat outlook was noted.
Following the quarterly report and commentary on growth drivers, Needham raised its price target on Viavi from $28 to $36 and kept a Buy rating, citing strong expansion tied to the data center ecosystem and aerospace and defense sales. Separately, Viavi introduced a new product, the Cesium-less ePRTC360+ holdover solution. The company describes this device as an alternative to cesium atomic clocks that meets the ITU-T G.8272.1 standard for Enhanced Primary Reference Time Clock holdover - a solution positioned to protect critical infrastructure from GNSS timing disruptions.
The combination of an insider sale, valuation commentary from InvestingPro, analyst target adjustments, and new product introductions provides a compact snapshot of recent activity surrounding Viavi. The Form 4 filing is the formal record of the insider transaction; further detail on valuation and performance metrics is available through the referenced InvestingPro Pro Research Report covering Viavi and other US equities.
Contextual note - The facts presented here are limited to the transaction and company disclosures specified above, including the Form 4 filing, quarterly results, analyst action by Needham, and the product announcement. Additional interpretation or forward-looking conclusions are not included beyond the information the company and filings provided.